Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 7599 Anagram Dr EDEN PRAIRIE MN 55344-7399 |
Tel: | N/A |
Website: | https://nmtc1.com |
IR: | See website |
Key People | ||
David A. Rosa President, Chief Executive Officer, Director | Mark Christianson Co-Founder, Business Development Director - Medical Sales Liaison | Ronald Mcclurg Chief Financial Officer |
Christopher R. Volker Chief Operating Officer | Steve Mertens Chief Technology Officer |
Business Overview |
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. The Company is focused on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, spinal cord stimulation, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure and artificial intelligence. Its Evo cortical electrode technology records, monitors, and stimulates brain tissue on the surface of the brain. Its products include strip/grid, depth electrodes (sEEG Products) and electrode cable assembly products. |
Financial Overview |
For the three months ended 31 December 2023, Neuroone Medical Technologies Corp revenues decreased 38% to $978K. Net loss increased 93% to $3.3M. Revenues reflect Collaborations revenue decrease from $1.5M to $0K. Higher net loss reflects General and administrative - Balancing increase of 37% to $1.9M (expense), Stock-based Compensation in R&D increase of 46% to $65K (expense), Other income decrease of 12% to $46K (income). |
Employees: | 16 as of Sep 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $27.62M as of Dec 31, 2023 |
Annual revenue (TTM): | $2.86M as of Dec 31, 2023 |
EBITDA (TTM): | -$13.34M as of Dec 31, 2023 |
Net annual income (TTM): | -$13.47M as of Dec 31, 2023 |
Free cash flow (TTM): | -$13.61M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 25,930,926 as of Feb 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |